CEL-SCI extends clinical trials for head/neck cancer drug
Pharmaceutical company CEL-SCI has begun phase III clinical trials for its immunotherapy drug Multikine in Hungary. Studies are already ongoing at 12 clinical sites in the U.S., Canada, Poland, and India. The total study is expected to enroll about 880 head and neck cancer patients in more than 40 hospitals in nine countries. The goal is to establish Multikine as a first-line standard of care therapy in treating newly diagnosed

